In fact, the extent of T1AM degradation would depend on MAO-B tissue expression levels and on pathological conditions altering MAO-B promoter activity, including diabetes, inflammation, thyroid diseases, or aging. This evidence concerns the gene MAOB and diabetes mellitus.